


**AMENDMENT TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently amended) A compound of formula



or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof

wherein

~~G<sub>1</sub> and G<sub>2</sub> are independently L<sub>1</sub>-Cy<sub>1</sub> or L<sub>2</sub>-Cy<sub>2</sub>, provided that when R<sub>1</sub> and R<sub>1a</sub> or R<sub>4</sub> and R<sub>4a</sub> taken together form O or S, then G<sub>1</sub> is L<sub>2</sub>-Cy<sub>2</sub> and G<sub>2</sub> is L<sub>1</sub>-Cy<sub>1</sub>, or when R<sub>2</sub> and R<sub>2a</sub> or R<sub>3</sub> and R<sub>3a</sub> taken together form O or S, then G<sub>1</sub> is L<sub>1</sub>-Cy<sub>1</sub> and G<sub>2</sub> is L<sub>2</sub>-Cy<sub>2</sub>;~~

G<sub>1</sub> is L<sub>1</sub>-Cy<sub>1</sub>;

G<sub>2</sub> is L<sub>2</sub>-Cy<sub>2</sub>;

Cy<sub>1</sub> and Cy<sub>2</sub> are independently selected from ~~optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclenyl, optionally substituted fused arylecycloalkyl, optionally substituted fused arylecycloalkenyl, optionally substituted fused arylheterocyclyl, optionally substituted fused arylheterocyclenyl, optionally substituted fused heteroaryl cycloalkyl, optionally substituted fused heteroaryl cycloalkenyl, optionally substituted fused heteroaryl heterocyclyl and optionally substituted fused heteroaryl heterocyclenyl;~~

~~L<sub>1</sub> is O, NR<sub>5</sub>, S(O)<sub>p</sub>, S(O)<sub>p</sub>NR<sub>5</sub>, C(X)Y or L<sub>3</sub>-Q-L<sub>4</sub>-Q'-L<sub>5</sub>;~~

L<sub>1</sub> is -S(O)<sub>2</sub>-;

L<sub>2</sub> is C<sub>(1-4)</sub> alkylene;

~~L<sub>3</sub> and L<sub>5</sub> are independently absent, optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene;~~

~~L<sub>4</sub> is optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene;~~

~~Q and Q' are independently absent, O, S, NR<sub>5</sub>, S(O)<sub>p</sub>, S(O)<sub>p</sub>NR<sub>5</sub> or C(X)Y;~~

A is ~~CH~~ or N;

R<sub>1</sub>, R<sub>1a</sub>, R<sub>2</sub>, R<sub>2a</sub>, ~~R<sub>3</sub>, R<sub>3a</sub>~~, R<sub>4</sub> and R<sub>4a</sub> are independently selected from hydrogen, carboxy, alkoxy carbonyl, Y<sub>1</sub>Y<sub>2</sub>NCO, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl, ~~or R<sub>1</sub> and R<sub>1a</sub>, R<sub>2</sub> and R<sub>2a</sub>, R<sub>3</sub> and R<sub>3a</sub>, or R<sub>4</sub> and R<sub>4a</sub> taken together form O or S;~~


R<sub>3</sub> and R<sub>3a</sub> taken together form O;

~~m and n are independently 0, 1 or 2, provided that m and n are not both 0 and further provided that when R<sub>1</sub> and R<sub>1a</sub> taken together form O or S, n is 1 and when R<sub>4</sub> and R<sub>4a</sub> taken together form O or S, m is 1;~~

m is 1;

n is 1; and

~~L<sub>2</sub> is absent or a group of formula~~



~~R<sub>5</sub> is hydrogen, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, R<sub>6</sub>O(CH<sub>2</sub>)<sub>v</sub>, R<sub>6</sub>O<sub>2</sub>C(CH<sub>2</sub>)<sub>x</sub>, Y<sub>1</sub>Y<sub>2</sub>NC(O)(CH<sub>2</sub>)<sub>x</sub>, or Y<sub>1</sub>Y<sub>2</sub>N(CH<sub>2</sub>)<sub>v</sub>;~~

~~R<sub>6</sub> is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted heteroaralkyl;~~

~~Y<sup>1</sup> and Y<sup>2</sup> Y<sub>1</sub> and Y<sub>2</sub> are independently hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or Y<sub>1</sub> and Y<sub>2</sub> Y<sup>1</sup> and Y<sup>2</sup> taken together with the N through which Y<sub>1</sub> and Y<sub>2</sub> Y<sup>1</sup> and Y<sup>2</sup> are linked form a monocyclic heterocyclyl;~~

~~R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> and R<sub>10</sub> are independently selected from hydrogen, hydroxy, alkoxy, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl and optionally substituted heteroaralkyl, provided that only one of R<sub>7</sub> and R<sub>8</sub> or one of R<sub>9</sub> and R<sub>10</sub> is hydroxy or alkoxy, and further provided when R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> and R<sub>10</sub> is hydroxy or alkoxy, then the hydroxy or alkoxy is not  $\alpha$  substituted to a N, O or S in Z;~~

~~X is O or S;~~

~~Y is absent or is selected from O, S and NR<sub>5</sub>;~~

~~Z is absent or is selected from optionally substituted lower alkenylene, optionally substituted lower alkynylene, O, S(O)<sub>p</sub>, NR<sub>5</sub>, NR<sub>5</sub>C(O) and C(O)NR<sub>5</sub>;~~

~~x is 1, 2, 3 or 4;~~

~~v is 2, 3 or 4;~~

~~p is 1 or 2; and~~

~~q and r are independently 0, 1, 2 or 3, provided that q and r are not both 0;~~

2. (Currently amended) A compound according to claim 1 wherein Cy<sub>2</sub> contains at least one nitrogen atom and when Cy<sub>2</sub> is optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted fused phenylecycloalkyl or optionally substituted fused phenylcycloalkenyl, then said nitrogen atom is a basic nitrogen atom.


3-4. (Cancelled)

5. (Currently amended) A compound according to claim 4-1 wherein ~~R<sub>3</sub> and R<sub>3a</sub> taken together are O-~~ and R<sub>1</sub>, R<sub>1a</sub>, R<sub>2</sub>, R<sub>2a</sub>, and R<sub>4</sub> are hydrogen, and R<sub>4a</sub> is hydrogen or optionally substituted alkyl.

6. (Currently amended) A compound according to claim 4-1 wherein ~~R<sub>3</sub> and R<sub>3a</sub> taken together are O-~~ R<sub>1</sub>, R<sub>2</sub>, R<sub>2a</sub>, and R<sub>4</sub> are hydrogen; and R<sub>1a</sub> and R<sub>4a</sub> are independently selected from hydrogen, carboxy, alkoxycarbonyl, Y<sub>1</sub>Y<sub>2</sub>NCO or optionally substituted alkyl.

7-8. (Cancelled)

9. (Currently amended) A compound according to claim 4 wherein L<sub>2</sub> is alkylene of one to three carbon atoms ~~or a group of formula~~



wherein Z is NR<sub>5</sub>; ~~q is 2; r is 0; R<sub>5</sub> is hydrogen or optionally substituted alkyl; and R<sub>7</sub> and R<sub>8</sub> are hydrogen.~~

10-11. (Cancelled)

12. (Original) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

13. (Withdrawn) A method for treating a patient suffering from a physiological condition capable of being modulated by inhibiting activity of Factor Xa comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.

14-15. (Cancelled)

16. (Withdrawn) A method of inhibiting Factor Xa comprising contacting a Factor Xa

inhibitory amount of a compound according to claim 1 with a composition containing Factor Xa.

17-22. (Cancelled)

23. (Currently amended) A compound according to claim ~~19~~1 wherein Cy<sub>2</sub> is optionally substituted with one or more groups selected from amino, carbamoyl, acylamino, heteroaryl, heterocyclenyl, heterocyclyl, alkyl, alkyloxycarbonyl, amidino, hydroxy, alkoxy, aryl, isourea, guanidino, acylhydrazino, acyl, cyano, carboxy, sulfamoyl, or halo.

24. (Currently amended) A compound according to claim ~~19~~1 wherein Cy<sub>2</sub> is optionally substituted with one or more groups selected from amino, hydroxy, or halo.

25-27 (Cancelled)

28. (Currently amended) A compound according to claim ~~19~~1 wherein Cy<sub>1</sub> is optionally substituted with one of more groups selected from amino, halo, hydroxyl, aryl, heteroaryl, amidino, alkyl, acylamino, carbamoyl, cyano, alkoxy, nitro, carbamate, sulfamyl.


29. (Currently amended) A compound according to claim ~~19~~1 wherein at least one of R<sub>1</sub> or R<sub>4</sub> is alkoxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxycarbonylalkyl, hydroxyalkyl, acylalkyl, acylaminoalkyl or carbamoylalkyl; and the corresponding R<sub>1a</sub> or R<sub>4a</sub> is hydrogen.

30. (Cancelled)

31. (Currently amended) A compound according to claim ~~19~~1 wherein at least one of R<sub>1</sub> or R<sub>4</sub> is lower alkyl, carboxy, alkoxycarbonyl or carbamoyl, and the corresponding R<sub>1a</sub> or R<sub>4a</sub> is hydrogen.

32-33. (Cancelled)

34. (Currently amended) A compound according to claim ~~19~~1 having the formula IIb



or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof,

wherein

~~R<sub>1</sub>, R<sub>1a</sub>, R<sub>2</sub>, R<sub>2a</sub>, R<sub>4</sub>, and R<sub>4a</sub>, L<sub>1</sub> and Cy<sub>1</sub> are as defined in claim 1; are independently selected from hydrogen, carboxy, alkoxycarbonyl, Y<sub>1</sub>Y<sub>2</sub>NC(O), optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl, or R<sub>1</sub> and R<sub>1a</sub>, R<sub>2</sub> and R<sub>2a</sub> or R<sub>4</sub> and R<sub>4a</sub> taken together form O or S; or R<sub>1</sub> and R<sub>2</sub> together with the carbon atoms through which R<sub>1</sub> and R<sub>2</sub> are linked form a cycloalkyl group, cycloalkenyl group, heterocyclyl group, or heterocyclenyl group; or R<sub>1a</sub> and R<sub>2a</sub> are absent and R<sub>1</sub> and R<sub>2</sub> together with the carbon atoms through which R<sub>1</sub> and R<sub>2</sub> are linked form an aryl or heteroaryl group; or one or more of the pairs R<sub>1</sub> and R<sub>1a</sub> taken together with the carbon atom through which they are linked form a 3 to 7 membered cycloalkyl or cycloalkenyl group; or R<sub>2</sub> and R<sub>2a</sub> taken together with the carbon atom through which they are linked form a 3 to 7 membered cycloalkyl or cycloalkenyl group; or R<sub>4</sub> and R<sub>4a</sub> taken together with the carbon atom through which they are linked form a 3 to 7 membered cycloalkyl or cycloalkenyl group;~~

~~Cy<sub>1</sub> are independently selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclenyl, optionally substituted fused arylecycloalkyl, optionally substituted fused arylecycloalkenyl, optionally substituted fused arylheterocyclyl, optionally substituted fused arylheterocyclenyl, optionally substituted fused heteroarylecycloalkyl, optionally substituted fused heteroarylecycloalkenyl, optionally substituted fused heteroarylheterocyclyl and optionally substituted fused heteroarylheterocyclenyl;~~


~~L<sub>1</sub> is absent, O, NR<sub>5</sub>, S(O)<sub>p</sub>, S(O)<sub>p</sub>NR<sub>5</sub>, C(X)Y or L<sub>3</sub>-Q-L<sub>4</sub>-Q'-L<sub>5</sub>, C(O)Y-C(X)Y, C(X)YC(O),~~

~~-C(C)NR<sub>5</sub>-S(O)<sub>p</sub>, or -C(O)C(O)NR<sub>5</sub>S(O)<sub>p</sub>; and~~

R<sub>13</sub> and R<sub>14</sub> are independently hydrogen, lower alkyl, aryl, heteroaryl, amino, acylaminoalkyl,

alkoxycarbonylalkyl, carbamoylalkyl or alkoxyalkyl; or  $R_{13}$  and  $R_{14}$  together with the carbon atoms through which  $R_{13}$  and  $R_{14}$  are linked form a cycloalkyl group, cycloalkenyl group, heterocyclyl group, heterocyclenyl group, aryl group or heteroaryl group.

35. (Currently amended) A compound according to claim ~~19~~1 having the formula IIc



or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof,

wherein:

$Cy_1$  is thiaheteroaryl or azaheteroaryl,


$L_1$  is  ~~$-S(O)_2-$ ,  $-S(O)_2-$  alkylene,  $-S(O)_2-$  alkyenylene or  $-S(O)_2-$  alkynylene;~~

$R_1$ ,  $R_{1a}$ ,  $R_2$ , and  $R_{2a}$  are independently hydrogen, alkyl, carboxyl, alkoxycarbonyl, or carbamoyl;

$L_2$  is methylene; and

$Cy_2$  is azaheteroaryl, ~~azaheterocyclyl, azaheterocyclenyl,~~ fused azaheteroaryl cycloalkyl, fused azaheteroaryl cycloalkenyl, fused heteroaryl azacycloalkyl or fused heteroaryl azacycloalkenyl.

36. (Currently amended) A compound according to claim ~~19~~1 having the formula IIId



wherein  $R_{17}$  and  $R_{18}$  are independently hydrogen or halogen;

$J_1$  is S or NH;

$J_2$  is CH or N; and

$R_2$  is hydrogen, alkyl, carboxyl, alkoxycarbonyl, or carbamoyl.

37-44. (Cancelled)

45. (Withdrawn, but currently amended) A method for treating a patient suffering from a physiological condition capable of being modulated by inhibiting activity of Factor Xa comprising administering to said patient a pharmaceutically effective amount of a compound according to claim ~~4949~~.

46. (Withdrawn, but currently amended) A method for treating a patient suffering from a physiological condition capable of being modulated by directly inhibiting activity of both Factor Xa and Factor IIa comprising administering to said patient a pharmaceutically effective amount of a compound according to claim ~~4349~~.

47. (Original) A method for treating a patient suffering from a physiological condition capable of being modulated by directly inhibiting activity of both Factor Xa and Factor IIa comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 35.

48. (Original) A method for treating a patient suffering from a physiological condition

capable of being modulated by directly inhibiting activity of both Factor Xa and Factor IIa comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 36.

49. (New) A compound according to claim 1 selected from the group consisting of
- 1-(2-Amino-quinoxalin-6-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-thieno[2,3-c]pyridin-2-ylmethyl-piperazin-2-one,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-thieno[3,2-c]pyridin-2-ylmethyl-piperazin-2-one,  
1-(2-Amino-quinolin-6-ylmethyl)-4-(6-chloro-thieno[2,3-b]pyridine-2-sulfonyl)-piperazin-2-one,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(1-chloro-isoquinolin-6-ylmethyl)-piperazin-2-one,  
1-(7-Amino-thieno[2,3-c]pyridin-2-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-quinolin-6-ylmethyl-piperazin-2-one,  
1-(2-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one,  
1-(4-Amino-thieno[3,2-c]pyridin-2-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-isoquinolin-6-ylmethyl-piperazin-2-one,  
1-(2-Amino-quinolin-6-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one,  
1-(1-Amino-isoquinolin-6-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one,  
1-(1-Amino-isoquinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one,  
1-(4-Amino-thieno[3,2-c]pyridin-2-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one,  
1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-thieno[2,3-b]pyridine-2-sulfonyl)-piperazin-2-one,  
1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-1H-benzoimidazole-2-sulfonyl)-piperazin-2-one,  
(S)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-3-ethyl-piperazin-2-one,  
(S)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-3-methyl-piperazin-2-one,  
(+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-methyl-piperazin-2-one,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(5-oxy-1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(1-methyl-1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one,  
4-(6-Chloro-thieno[2,3-b]pyridine-2-sulfonyl)-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-

one,  
4-(6-Bromo-benzo[b]thiophene-2-sulfonyl)-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one,  
4-(5'-Chloro-[2,2']bithiophenyl-5-sulfonyl)-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one,  
2-{2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-pyrrolo[3,2-c]pyridin-1-yl}-acetamide,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-[1-(2-hydroxy-ethyl)-1H-pyrrolo[3,2-c]pyridin-2-ylmethyl]-piperazin-2-one,  
4-(6-Chloro-1H-benzimidazole-2-sulfonyl)-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one,  
4-(1H-Benzimidazole-2-sulfonyl)-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-piperazin-2-one,  
4-(6-Chloro-thieno[2,3-b]pyridine-2-sulfonyl)-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-piperazin-2-one,  
4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazine-2-carboxylic acid amide,  
(3S,5S)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-3,5-dimethyl-piperazin-2-one,  
1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one,  
1-(S)-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-3-methyl-piperazin-2-one,  
1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid methylamide,  
1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid ethylamide,  
1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid dimethylamide,  
1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-(morpholine-4-carbonyl)-piperazin-2-one,  
(+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid amide,  
1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid methylamide,

1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid ethylamide,

1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid dimethylamide,

1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-6-(morpholine-4-carbonyl)-piperazin-2-one, and

1-(3-Amino-1H-indazol-6-ylmethyl)-4-(6-chloro-benzo[b]thiophene-2-sulfonyl)-piperazin-2-one, or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.